Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity has been associated with genetic and sporadic forms of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253120301888 |
| _version_ | 1828884633019744256 |
|---|---|
| author | Joanna A. Korecka Ria Thomas Anthony J. Hinrich Alyssa M. Moskites Zach K. Macbain Penelope J. Hallett Ole Isacson Michelle L. Hastings |
| author_facet | Joanna A. Korecka Ria Thomas Anthony J. Hinrich Alyssa M. Moskites Zach K. Macbain Penelope J. Hallett Ole Isacson Michelle L. Hastings |
| author_sort | Joanna A. Korecka |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity has been associated with genetic and sporadic forms of PD and, thus, reducing LRRK2 function is a promising therapeutic strategy. We have previously reported that an antisense oligonucleotide (ASO) that blocks splicing of LRRK2 exon 41, which encodes part of the kinase domain, reverses aberrant endoplasmic reticulum (ER) calcium levels and mitophagy defects in PD patient-derived cell lines harboring the LRRK2 G2019S mutation. In this study, we show that treating transgenic mice expressing human wild-type or G2019S LRRK2 with a single intracerebroventricular injection of ASO induces exon 41 skipping and results in a decrease in phosphorylation of the LRRK2 kinase substrate RAB10. Exon 41 skipping also reverses LRRK2 kinase-dependent changes in LC3B II/I ratios, a marker for the autophagic process. These results demonstrate the potential of LRRK2 exon 41 skipping as a possible therapeutic strategy to modulate pathogenic LRRK2 kinase activity associated with PD development. |
| first_indexed | 2024-12-13T11:10:53Z |
| format | Article |
| id | doaj.art-c35d1d9940544cb3b606f79c91e2929b |
| institution | Directory Open Access Journal |
| issn | 2162-2531 |
| language | English |
| last_indexed | 2024-12-13T11:10:53Z |
| publishDate | 2020-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj.art-c35d1d9940544cb3b606f79c91e2929b2022-12-21T23:48:45ZengElsevierMolecular Therapy: Nucleic Acids2162-25312020-09-0121623635Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic MiceJoanna A. Korecka0Ria Thomas1Anthony J. Hinrich2Alyssa M. Moskites3Zach K. Macbain4Penelope J. Hallett5Ole Isacson6Michelle L. Hastings7Neuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA; Corresponding author: Joanna A. Korecka, Neuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA.Neuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USACenter for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USANeuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USANeuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USANeuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USANeuroregeneration Research Institute, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USACenter for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA; Corresponding author: Michelle L. Hastings, Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity has been associated with genetic and sporadic forms of PD and, thus, reducing LRRK2 function is a promising therapeutic strategy. We have previously reported that an antisense oligonucleotide (ASO) that blocks splicing of LRRK2 exon 41, which encodes part of the kinase domain, reverses aberrant endoplasmic reticulum (ER) calcium levels and mitophagy defects in PD patient-derived cell lines harboring the LRRK2 G2019S mutation. In this study, we show that treating transgenic mice expressing human wild-type or G2019S LRRK2 with a single intracerebroventricular injection of ASO induces exon 41 skipping and results in a decrease in phosphorylation of the LRRK2 kinase substrate RAB10. Exon 41 skipping also reverses LRRK2 kinase-dependent changes in LC3B II/I ratios, a marker for the autophagic process. These results demonstrate the potential of LRRK2 exon 41 skipping as a possible therapeutic strategy to modulate pathogenic LRRK2 kinase activity associated with PD development.http://www.sciencedirect.com/science/article/pii/S2162253120301888LRRK2antisense oligonucleotideParkinson’s diseaseLRRK2 BAC micesplicingRAB10 |
| spellingShingle | Joanna A. Korecka Ria Thomas Anthony J. Hinrich Alyssa M. Moskites Zach K. Macbain Penelope J. Hallett Ole Isacson Michelle L. Hastings Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice Molecular Therapy: Nucleic Acids LRRK2 antisense oligonucleotide Parkinson’s disease LRRK2 BAC mice splicing RAB10 |
| title | Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice |
| title_full | Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice |
| title_fullStr | Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice |
| title_full_unstemmed | Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice |
| title_short | Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice |
| title_sort | splice switching antisense oligonucleotides reduce lrrk2 kinase activity in human lrrk2 transgenic mice |
| topic | LRRK2 antisense oligonucleotide Parkinson’s disease LRRK2 BAC mice splicing RAB10 |
| url | http://www.sciencedirect.com/science/article/pii/S2162253120301888 |
| work_keys_str_mv | AT joannaakorecka spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT riathomas spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT anthonyjhinrich spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT alyssammoskites spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT zachkmacbain spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT penelopejhallett spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT oleisacson spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice AT michellelhastings spliceswitchingantisenseoligonucleotidesreducelrrk2kinaseactivityinhumanlrrk2transgenicmice |